Verastem Inc
VSTM5.974USD
-0.106-1.74%
交易中 （美東）報價延遲15分鐘
307.62M總市值
虧損本益比TTM
關於 Verastem Inc 公司
Verastem, Inc. 是一家後期開發生物製藥公司。該公司的產品線專注於抑制癌症中促進癌細胞存活和腫瘤生長的關鍵信號通路的抗癌藥物，特別是快速加速纖維肉瘤 (RAF)/絲裂原活化蛋白激酶 (MEK) 抑制和粘着斑激酶 (FAK) 抑制。該公司的先進產品候選藥物 avutometinib 和 defactinib 正在進行臨牀前和臨牀研究，用於治療各種實體腫瘤，包括低級別漿液性卵巢癌 (LGSOC)、非小細胞肺癌 (NSCLC)、胰腺癌、結直腸癌 (CRC) 和黑色素瘤。Avutometinib 是一種口服小分子 RAF/MEK 鉗，可抑制 ras 肉瘤 (RAS)/RAF/MEK、ERK 絲裂原活化途徑激酶 (MAPK) 通路。 Defactinib 是一種口服 FAK 和富含脯氨酸的酪氨酸激酶 (PYK2) 抑制劑。
公司簡介
公司代碼VSTM
公司名稱Verastem Inc
上市日期Nov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
員工數量78
證券類型Ordinary Share
年結日Nov 08
公司地址117 Kendrick Street
城市NEEDHAM
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02494
電話17812924200
網址https://www.verastem.com/
公司代碼VSTM
上市日期Nov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
178.97K
-9.20%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Ms. Michelle Robertson
Ms. Michelle Robertson
Independent Director
Independent Director
15.97K
+109.10%
Mr. Matthew E. (Matt) Ros
Mr. Matthew E. (Matt) Ros
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Julissa Viana
Ms. Julissa Viana
Investor Relations
Investor Relations
--
--
Dr. Paul Bunn, M.D.
Dr. Paul Bunn, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
178.97K
-9.20%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月30日 週三
更新時間: 7月30日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Balyasny Asset Management LP
8.71%
RTW Investments L.P.
7.73%
Logos Global Management LP
6.23%
The Vanguard Group, Inc.
6.23%
Point72 Asset Management, L.P.
6.08%
Other
65.02%
持股股東
持股股東
佔比
Balyasny Asset Management LP
8.71%
RTW Investments L.P.
7.73%
Logos Global Management LP
6.23%
The Vanguard Group, Inc.
6.23%
Point72 Asset Management, L.P.
6.08%
Other
65.02%
股東類型
持股股東
佔比
Hedge Fund
37.39%
Investment Advisor/Hedge Fund
19.69%
Investment Advisor
14.09%
Venture Capital
9.03%
Private Equity
7.93%
Research Firm
4.39%
Individual Investor
0.92%
Bank and Trust
0.09%
Insurance Company
0.03%
Other
6.43%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
221
44.66M
81.28%
-1.54M
2025Q1
244
43.61M
79.40%
-4.23M
2024Q4
235
34.35M
77.18%
-2.65M
2024Q3
242
27.08M
67.33%
+202.45K
2024Q2
244
15.08M
59.39%
-6.47M
2024Q1
256
17.10M
67.53%
-4.40M
2023Q4
273
17.07M
67.53%
-4.59M
2023Q3
291
17.14M
67.93%
-3.81M
2023Q2
301
16.47M
65.35%
+4.17M
2023Q1
312
8.40M
50.30%
-4.54M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Balyasny Asset Management LP
4.79M
8.71%
+842.05K
+21.34%
Mar 31, 2025
RTW Investments L.P.
4.25M
7.73%
+4.25M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.43M
4.42%
+118.60K
+5.13%
Mar 31, 2025
OrbiMed Advisors, LLC
2.86M
5.21%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
2.64M
4.81%
+1.74M
+193.84%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.33M
4.24%
+51.04K
+2.24%
Mar 31, 2025
Nantahala Capital Management, LLC
2.30M
4.18%
-1.45M
-38.75%
Mar 31, 2025
Marshall Wace LLP
2.23M
4.05%
+1.43M
+180.43%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Biotech ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
查看更多
SPDR S&P Biotech ETF
佔比0.11%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.06%
iShares Micro-Cap ETF
佔比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.03%
Fidelity Enhanced Small Cap ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
公告日期
類型
比率
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
May 31, 2023
Merger
12<1
